Lissoni Paolo, Rovelli Franco, Brivio Fernando, Zago Romano, Colciago Massimo, Messina Giuseppina, Mora Adelio, Porro Giorgio
Division of Radiation Oncology, St. Gerardo Hospital, Monza, Milan, Italy.
In Vivo. 2009 Jan-Feb;23(1):171-5.
The recent advances in the analysis of tumor immunobiology suggest the possibility of biologically manipulating the efficacy and toxicity of cancer chemotherapy by endogenous or exogenous immunomodulating substances. Aloe is one of the of the most important plants exhibiting anticancer activity and its antineoplastic property is due to at least three different mechanisms, based on antiproliferative, immunostimulatory and antioxidant effects. The antiproliferative action is determined by anthracenic and antraquinonic molecules, while the immunostimulating activity is mainly due to acemannan.
A study was planned to include 240 patients with metastatic solid tumor who were randomized to receive chemotherapy with or without Aloe. According to tumor histotype and clinical status, lung cancer patients were treated with cisplatin and etoposide or weekly vinorelbine, colorectal cancer patients received oxaliplatin plus 5-fluorouracil (5-FU), gastric cancer patients were treated with weekly 5-FU and pancreatic cancer patients received weekly gemcitabine. Aloe was given orally at 10 ml thrice/daily.
The percentage of both objective tumor regressions and disease control was significantly higher in patients concomitantly treated with Aloe than with chemotherapy alone, as well as the percent of 3-year survival patients.
This study seems to suggest that Aloe may be successfully associated with chemotherapy to increase its efficacy in terms of both tumor regression rate and survival time.
肿瘤免疫生物学分析的最新进展表明，有可能通过内源性或外源性免疫调节物质对癌症化疗的疗效和毒性进行生物学调控。芦荟是表现出抗癌活性的最重要植物之一，其抗肿瘤特性至少基于三种不同机制，即抗增殖、免疫刺激和抗氧化作用。抗增殖作用由蒽类和蒽醌类分子决定，而免疫刺激活性主要归因于乙酰化甘露聚糖。
计划开展一项研究，纳入240例转移性实体瘤患者，将其随机分为接受化疗联合或不联合芦荟治疗两组。根据肿瘤组织类型和临床状况，肺癌患者接受顺铂和依托泊苷或每周长春瑞滨治疗，结直肠癌患者接受奥沙利铂加5-氟尿嘧啶（5-FU）治疗，胃癌患者接受每周5-FU治疗，胰腺癌患者接受每周吉西他滨治疗。芦荟以每日三次、每次10 ml口服给药。
同时接受芦荟治疗的患者客观肿瘤退缩率和疾病控制率均显著高于单纯接受化疗的患者，3年生存患者的比例也是如此。
本研究似乎表明，芦荟可能成功地与化疗联合使用，以提高其在肿瘤退缩率和生存时间方面的疗效。
